Mohammad AskarPublic working copy · medical review pending

Retinal drug toxicity · 180

Drug-induced retinal toxicity

Recognise the retinal pattern, establish the exact exposure and coordinate the response with the prescribing team.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Drug exposure is a clue, not proof. Confirm suspicious findings and distinguish degeneration, vascular injury, oedema and crystals before changing essential systemic treatment.

Terminology and draft status

Terminology review is not complete. No new WHO UMD entry verification is claimed for this copy; pending entries and limits are recorded in terminology.md.

01Start with pattern and exposure

Record drug, route, current and cumulative dose, duration, renal function, co-medication and symptom timing. Retinal pigment epithelium (RPE) and photoreceptors are metabolically active, but melanin binding is not one established mechanism for every toxic drug. The four useful patterns are outer-retinal/RPE damage, vascular ischaemia, cystoid macular oedema (CME) and crystalline deposits. 1

Compare both eyes, prior OCT and fundus images and alternative diagnoses. A temporal association, a flying-saucer appearance or crystals alone does not establish drug causality; inherited, inflammatory, diabetic and vascular disease can coexist. 1

02Detect HCQ toxicity before advanced loss

Hydroxychloroquine (HCQ) and chloroquine (CQ) can damage photoreceptors and RPE. OCT may show parafoveal or pericentral outer-retinal thinning and ellipsoid-zone (EZ) disruption; central foveal sparing can produce the flying-saucer sign. Bull’s-eye maculopathy is a late appearance, not an early screening target. FAF maps altered autofluorescence and atrophy; neither hyperautofluorescence nor a normal-looking fundus is decisive alone. 1

AAO 2025 revision, published 2026, retains a daily HCQ limit ≤5 mg/kg real body weight and highlights dose, duration, renal disease, tamoxifen and older starting age. For severe obesity it gives additional caution around 400 mg/day. These are prescribing-team risk limits, not a safe-dose guarantee; CQ requires its own dosing guidance. 2

The current AAO approach uses OCT with wide-pattern FAF as primary screening tools; visual fields and mfERG are confirmatory. Look for both parafoveal and pericentral patterns regardless of ancestry. A 10-2, a wider 24-2/30-2 or a combined 24-2C strategy is selected to cover the pattern; the original mandatory 30-2 for every Asian patient is too rigid. 2

Obtain baseline fundus, OCT and FAF close to starting HCQ. Annual screening is advised; in patients without significant risk it may be deferred during the first 5 years. Higher-risk eyes need earlier surveillance. The export’s 6–12-month baseline window and renal stage 3+ are retained as historical working details, not substituted for the separate German S1 045-016/July 2025 protocol, whose discrepancy still needs direct source-image reconciliation. 2

Repeat or corroborate uncertain results before labelling toxicity and discuss the systemic benefit with the prescriber. Mild toxicity may remain stable after stopping, whereas extensive EZ/outer nuclear layer or RPE damage can progress for years. Neither inevitable progression in every eye nor automatic unsupervised withdrawal is justified. 2

03Recognise other outer-retinal patterns

Thioridazine is generally more retinotoxic than chlorpromazine; original daily thresholds >800 mg and >2400 mg respectively are unverified historical examples, not safe lower-dose boundaries. Pentosan polysulfate for interstitial cystitis can produce a pigmentary maculopathy resembling pattern dystrophy; record cumulative exposure and arrange specialist assessment rather than diagnosing from colour alone. 1

MEK inhibitors may cause multifocal subretinal fluid resembling central serous chorioretinopathy (CSC; original RCS). Absence of a focal FA hotspot can be a clue, not an absolute discriminator. Clofazimine and deferoxamine are also original toxicity topics; reversibility after deferoxamine withdrawal varies and is not assured. Coordinate oncology or other systemic treatment changes. 1

04Treat suspected vascular drug injury as urgent

Intraocular aminoglycosides such as amikacin or gentamicin, especially with dosing or preparation errors, can cause severe retinal ischaemia. Urgently establish the exposure and involve vitreoretinal/toxicology expertise. The original obligatory immediate vitrectomy and hopeless prognosis without it are unsupported universal claims; management depends on drug, dose, route and timing, and surgery cannot guarantee reversal of established damage. 1

Vancomycin-associated haemorrhagic occlusive retinal vasculitis (HORV) can be delayed and severe. A hypersensitivity mechanism is proposed, not proved in each case. Examine both eyes and exposure histories; the original claim of bilateral disease after exposure of only one eye remains unverified and must not be treated as a universal mechanism. Avoid reflex repeat vancomycin pending urgent specialist review. 1

Interferon-alpha may be associated with cotton-wool spots and small haemorrhages, often without symptoms, but neither complete reversibility nor an excellent prognosis is guaranteed. Talc from injected crushed preparations can embolise small retinal vessels, causing crystals, ischaemia and neovascularisation; assess systemic harm and retinal complications. 1

05Distinguish oedema from crystalline cavitation

Prostaglandin-analogue associated CME is a concern particularly with disrupted lens capsule, complicated surgery or other retinal risk. Pseudophakia alone does not establish causality or require stopping all prostaglandins. Assess competing postoperative, inflammatory, diabetic and vascular causes before altering glaucoma control. 1

Fingolimod-associated macular oedema (FAME) is described around 0.5% in the original; this is not a universal individual risk. Baseline assessment and review around 3–4 months are original monitoring anchors; new symptoms require earlier review and the exact current product/disease protocol remains to be checked. Management, including possible interruption or anti-inflammatory treatment, is coordinated with neurology. 1

Tamoxifen may produce reflective deposits, foveal cavitation or oedema and later atrophy. Toxicity can occur at conventional dosing; the original >20 mg/day is not a safe boundary, and its annual-screening rule is unverified. Crystals can persist and OCT cavities are not automatically leaking CME. Canthaxanthin and methoxyflurane are additional original crystalline-retinopathy exposures; location and functional impact vary. 1

06Agree an individual monitoring and action plan

Document baseline function and imaging, the suspected pattern and the confidence of attribution. Arrange corroborating tests where appropriate and communicate the severity and uncertainty to the prescribing team. A potentially sight-saving systemic drug should not be stopped solely because of one unreliable test, while acute toxic injury must not wait for repeated routine tests. 1

Agree an individual monitoring and action plan
DrugMechanism/patternMonitoring and limitSignsPrognosis
HCQPhotoreceptor/RPE toxicity≤5 mg/kg real weight; annual OCT/FAF, risk-adapted timingEZ change, flying-saucer, late bull’s-eyeMild may stabilise; severe may progress after stopping
Vancomycin intraocularPossible hypersensitivity/HORVUrgent review of delayed visual lossHaemorrhagic occlusive vasculitis; check both exposuresOften severe, outcome variable
Interferon-alphaCapillary injury associationAssess symptoms and severityCotton-wool spots/microhaemorrhagesOften improves, not universally reversible
MEK inhibitorsMultifocal subretinal fluidCoordinate oncology monitoringCSC-like fluid; absent FA hotspot not absoluteOften reversible, drug/eye dependent
FingolimodFAMEBaseline and around 3–4 months; symptoms soonerMacular oedema; original ~0.5% not universalIndividual stop/continue plan, recovery not guaranteed
TamoxifenDeposits/cavitation or CMEOriginal >20 mg/day/annual rule unverified, not safe cutoffCrystals, cavities, RPE/outer-retinal damageDeposits may persist; functional recovery varies
AminoglycosidesDirect retinal injury after intraocular exposureUrgently identify dose/route and obtain retinal expertiseSevere ischaemia, especially dosing errorsNo automatic vitrectomy cure or fixed prognosis
Pentosan polysulfatePigmentary maculopathyRecord cumulative cystitis-treatment exposure; screening protocol pendingPattern-dystrophy-like RPE changesAtrophy may persist or progress; variable
What are the main learning points?

Drug exposure is a clue, not proof. Confirm suspicious findings and distinguish degeneration, vascular injury, oedema and crystals before changing essential systemic treatment.

When is assessment urgent?

Acute visual loss after an intraocular drug, a dosing error, haemorrhagic vasculitis or severe inflammation needs immediate retinal assessment. Do not wait for a routine screening appointment.

References and access status

  1. 1
    Immutable original export; retinal toxicology lecture; attribution unchecked

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    AAO 2025 revision / 2026 HCQ screening statement

    Selected indexed official recommendation sections read 16 November 2026: dose/risk, primary and confirmatory tests, baseline/annual timing and progression. Not complete figures, cited studies or German S1 source-image reconciliation.

Original lecture link